TrialLeukemia & lymphoma2023

Point-of-care anti-CD19 chimeric antigen receptor T-cell therapy for relapsed/refractory follicular lymphoma.

Shalev Fried et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.